Semaglutide vs Tesofensine
A side-by-side research comparison of Semaglutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Semaglutide | Tesofensine |
|---|---|---|
| Full name | Semaglutide (GLP-1 Receptor Agonist) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 4,114 Da | 329.4 Da |
| Half-life | 7 days (168 hours) | 8-10 days |
| Bioavailability | High (SubQ ~89%), Moderate (oral ~1% with SNAC) | High (oral ~93%) |
| Typical dose | 0.25 mg → titrate up to 2.4 mg | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous injection | Oral |
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.